AbbVie "announced that the FDA has approved expanding the indication of QULIPTA for the preventive treatment of migraine in adults. The approval makes QULIPTA the first and only oral calcitonin gene-related peptide receptor antagonist approved to prevent episodic and chronic migraine. People living with chronic migraine experience headaches for 15 or more days per month, with at least eight of those days associated with migraine."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABBV:
